NPR logo

Pfizer to Pull Exubera as Profits Plunge

  • Download
  • <iframe src="https://www.npr.org/player/embed/15436580/15435869" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Pfizer to Pull Exubera as Profits Plunge

Your Health

Pfizer to Pull Exubera as Profits Plunge

Pfizer to Pull Exubera as Profits Plunge

  • Download
  • <iframe src="https://www.npr.org/player/embed/15436580/15435869" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Pharmaceutical giant Pfizer plans to cancel its diabetes drug Exubera. The company expected the drug to become a blockbuster, but prescriptions are still less than 1 percent of the insulin market. That makes Exubera one of the most expensive miscalculations in the pharmaceutical industry's history. The failure will cost Pfizer $2.8 billion. It said overall profit plunged 72 percent.